In the article on circulating tumor cells in metastatic prostate cancer in the October 1, 2008 issue of Clinical Cancer Research, there was an error in the Results section. The Baseline CTC and Prognosis paragraph should read, as follows: At the time of analysis 30% (28 of 94) of the Favorable (<5 CTC at baseline) and 66% (83 of 125) of the Unfavorable (<5 CTC at baseline) group patients had died (Fig. 1), with a median OS of 21.7 (95% CI, 21.3 months to Not Reached) and 11.5 months (95% CI, 9.3-13.7 months), respectively, (Log-rank P < 0.0001; Cox HR, 3.3; χ2 = 34.48; P < 0.0001).
de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302-9.
RSS Feeds